drugset / Trial / NCT03343145

A Study to Evaluate the Efficacy, Safety and Immunogenicity of Leucostim® Versus Neupogen® in Breast Cancer Patients

NCT03343145

Phase 3 Completed 143 enrolled Dong-A ST Co., Ltd.
RandomizedParallel-groupOpen-labelPrevention

Summary

A study to compare the efficacy, safety and immunogenicity of Leucostim® to those of Neupogen® in patients with breast cancer intended to be treated with TAC regimen as a myelosuppressive chemotherapy.

Timeline

Start
2017-01-12
Primary completion
2019-01-28
Completion
2019-07-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Leucostim Unknown 5 ug/kg Subcutaneous
Comparator filgrastim Protein / enzyme biologic 5 ug/kg Subcutaneous

Indications